ANI Pharmaceuticals price target raised to $94 from $87 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on ANI Pharmaceuticals to $94 from $87 and keeps a Buy rating on the shares. The company followed through on its goal to leverage its rare-disease commercial infrastructure through acquisitions, announcing an agreement to acquire Alimera Sciences (ALIM) and its on-market, growing, ophthalmology franchise, the analyst tells investors in a research note. The firm says Alimera brings a global franchise with two very-long-duration steroid intravitreal implants, Iluvien and Yutiq, for diabetic macular edema and chronic noninfections uveitis affecting the posterior segment, respectively.